The closing price of Dexcom Inc (NASDAQ: DXCM) was $135.38 for the day, up 1.76% from the previous closing price of $133.04. In other words, the price has increased by $+2.34 from its previous closing price. On the day, 3362179 shares were traded.
Ratios:
Our analysis of DXCM’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 101.95. For the most recent quarter (mrq), Quick Ratio is recorded 2.48 and its Current Ratio is at 2.84. In the meantime, Its Debt-to-Equity ratio is 1.25 whereas as Long-Term Debt/Eq ratio is at 1.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $165.
Raymond James Upgraded its Outperform to Strong Buy on April 17, 2023, whereas the target price for the stock was revised from $127 to $138.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 20 ’24 when Sylvain Jereme M sold 3,363 shares for $116.73 per share. The transaction valued at 392,563 led to the insider holds 71,142 shares of the business.
SAYER KEVIN R sold 37,325 shares of DXCM for $4,614,669 on Jan 16 ’24. The President, CEO and Chairman now owns 362,841 shares after completing the transaction at $123.63 per share. On Jan 16 ’24, another insider, Leach Jacob Steven, who serves as the EVP Chief Operating Officer of the company, sold 3,978 shares for $123.63 each. As a result, the insider received 491,819 and left with 262,499 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 52.19B and an Enterprise Value of 52.06B. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 103.29, and their Forward P/E ratio for the next fiscal year is 60.87. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.41 while its Price-to-Book (P/B) ratio in mrq is 25.22. Its current Enterprise Value per Revenue stands at 14.37 whereas that against EBITDA is 56.79.
Stock Price History:
Over the past 52 weeks, DXCM has reached a high of $139.55, while it has fallen to a 52-week low of $74.75. The 50-Day Moving Average of the stock is 123.48, while the 200-Day Moving Average is calculated to be 113.44.
Shares Statistics:
DXCM traded an average of 3.12M shares per day over the past three months and 4.28M shares per day over the past ten days. A total of 385.40M shares are outstanding, with a floating share count of 377.40M. Insiders hold about 2.10% of the company’s shares, while institutions hold 103.35% stake in the company. Shares short for DXCM as of Feb 29, 2024 were 16.65M with a Short Ratio of 5.34, compared to 18.56M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.32% and a Short% of Float of 4.89%.
Earnings Estimates
The firm’s stock currently is rated by 19 analysts. On average, analysts expect EPS of $0.27 for the current quarter, with a high estimate of $0.34 and a low estimate of $0.21, while EPS last year was $0.17. The consensus estimate for the next quarter is $0.39, with high estimates of $0.44 and low estimates of $0.33.
Analysts are recommending an EPS of between $1.88 and $1.57 for the fiscal current year, implying an average EPS of $1.75. EPS for the following year is $2.23, with 20 analysts recommending between $2.51 and $1.99.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 18 analysts. It ranges from a high estimate of $928M to a low estimate of $877.65M. As of the current estimate, Dexcom Inc’s year-ago sales were $720.74M, an estimated increase of 26.30% from the year-ago figure. For the next quarter, 18 analysts are estimating revenue of $1.05B, an increase of 24.30% less than the figure of $26.30% in the same quarter last year. There is a high estimate of $1.08B for the next quarter, whereas the lowest estimate is $1.02B.
A total of 22 analysts have provided revenue estimates for DXCM’s current fiscal year. The highest revenue estimate was $4.37B, while the lowest revenue estimate was $4.26B, resulting in an average revenue estimate of $4.33B. In the same quarter a year ago, actual revenue was $3.62B, up 19.40% from the average estimate. Based on 22 analysts’ estimates, the company’s revenue will be $5.15B in the next fiscal year. The high estimate is $5.3B and the low estimate is $4.99B. The average revenue growth estimate for next year is up 19.00% from the average revenue estimate for this year.
